Analyst Viewpoint
Rise in incidence of chronic diseases and introduction of advanced technologies are boosting the drug delivery systems market size. Drug delivery system is the process of precise administration of a pharmaceutical compound to achieve a therapeutic effect.
Surge in geriatric population is also driving the need for drug delivery systems with integrated connectivity, as the elderly population is more prone to chronic ailments.
Key players in the global drug delivery systems market are working on devising AI-enabled sensors that can encompass simplicity and precision in administration of dosages.
In line with the latest drug delivery systems industry trends, they are introducing novel drug delivery systems and smart drug delivery systems for targeted therapy to increase their industry share.
Drug delivery systems are devices that facilitate controlled administration of drug in the body in terms of time, rate, and place of release. These devices include syringes, injectable drug delivery solutions, and auto-injectors.
Key participants of the drug delivery systems market distribute their systems/devices/products to pharmaceutical companies or end-users through online, hospital, and retail pharmacies.
They are launching new devices abreast with better dosing features for complementing drug treatment outcomes. For instance, Ypsomed introduced YpsoMate, the first auto-injector for prefilled syringes with connectivity, in November 2021.
Biocompatible drug transporters include polysaccharides (dextran, starch, chitosan, etc.) and proteins (albumin, gelatin, collagen, etc.). Introduction of nanoparticles for drug delivery is creating lucrative drug delivery systems market opportunities for companies operating in the sector.
Inorganic nanocarriers such as gold, magnetic, and silica and nanoparticles such as dendrimers are being explored for encapsulating and delivering drugs to the target sites in the body.
Increase in number of product recalls is a prominent factor that is hampering drug delivery systems market growth. As per an article published by Drugwatch dated 2021, around 4500 drugs and devices witness recall from the shelves of the U.S. every year.
In June 2021, Smiths Medical initiated class I recall of Jelco Hypodermic Needle-Pro Fixed Needle Insulin Syringe due to improper graduated markings. These manufacturing defects can result in underdose or overdose of insulin.
Patients are increasingly preferring advanced drug delivery systems owing to reduced variability with respect to drug concentrations along with ability of delivering a drug in a more selective manner to the site with higher precision.
Such features of drug delivery systems have prompted patients to opt for self-administered devices. For instance, in May 2021, Gerresheimer AG presented an on-body drug delivery platform that is capable of delivering biologics.
Digitization of medical devices also provides benefits such as controlled dosage, needle-free injection, and better flexibility of self-administration. In December 2022, Biocorp received approval from the U.S. FDA for Mallya, its smart sensor, which connects with insulin devices on direct basis.
The sensor collects data and transmits it to a dedicated application. Better handling of medical data is thus raising the bar for the market.
As per the WHO, chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma, diabetes, and cancer account for more than 30% of fatalities across the globe.
Usage of smart drug delivery systems for targeted therapy is likely to help reduce these fatalities.
Aging population is more prone to chronic diseases. As per the United Health Foundation, the global population aged 65 and above rose by 16.9% in 2022.
Usage of effective drug delivery devices would help in managing chronic diseases with the desired accuracy.
Digitization in the healthcare sector has opened up various personalized options related to drug delivery. In other words, the same route of administration might not suit every age group.
Technology combined with requirement is thus fostering drug delivery systems market development.
As per drug delivery systems market analysis, North America accounted for large share of the global landscape in 2022. It is likely to remain the dominant region during the forecast period.
High share of North America can be ascribed to proactive measures undertaken by the U.S. Government such as the increase in COVID-19 vaccination drives during the peak of the pandemic.
As per an article published by CIHI dated April 2021, the year 2019-20 witnessed 3 million acute inpatient hospitalizations in Canada alone.
Furthermore, rise in adoption of novel drug delivery systems such as metered-dose inhalers and sensor-embedded devices for treating chronic diseases is augmenting the drug delivery systems market share of North America.
Europe also holds key share of the drug delivery systems business, led by high awareness regarding the importance of adopting advanced drug delivery devices among the geriatric population in the region.
Improvement in healthcare infrastructure in countries such as India and China is likely to fuel the market dynamics of Asia Pacific during the forecast period.
On the other hand, Latin America and Middle East & Africa are likely to constitute noticeable market share during the forecast period owing to the rise in number of asthmatic and diabetic patients in these regions.
Companies operating in the global drug delivery systems landscape are focusing on new product launches and expansion of manufacturing capacities to increase their market share.
In January 2023, Nemera inaugurated a novel manufacturing facility in Poland with the objective of expanding its production capacity of drug delivery solutions. Furthermore, in September 2022, Becton, Dickinson and Company introduced BD Effivax, the next-generation pre-fillable vaccine syringe.
Novartis AG, Amgen Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson Services, Ltd., Becton, Dickinson and Company, AstraZeneca plc, Baxter International, Inc., Bayer AG, and Boston Scientific Corporation are the leading companies functioning in the global drug delivery systems landscape.
These companies have been profiled in the drug delivery systems market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 40.1 Bn |
| Market Forecast (Value) in 2031 | US$ 71.6 Bn |
| Market Growth Rate (CAGR) | 6.8% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 40.1 Bn in 2022
It is projected to grow at a CAGR of 6.8% from 2023 to 2031
Introduction of advanced technologies and growth in incidence of chronic diseases
The targeted drug delivery segment accounted for the largest share in 2022
North America was the dominant region in 2022
Novartis AG, Amgen Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson Services, Ltd., Becton, Dickinson and Company, AstraZeneca plc, Baxter International, Inc., Bayer AG, and Boston Scientific Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug Delivery Systems Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Drug Delivery Systems Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Drug Delivery Systems Market Analysis and Forecast, by Type of Delivery System
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type of Delivery System, 2017–2031
6.3.1. Intrauterine Implants
6.3.2. Prodrug Implants
6.3.3. Polymeric Drug Delivery
6.3.4. Targeted Drug Delivery
6.4. Market Attractiveness Analysis, by Type of Delivery System
7. Global Drug Delivery Systems Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Infectious Diseases
7.3.2. Oncology
7.3.3. Ophthalmology
7.3.4. Urology
7.3.5. Diabetes
7.3.6. CNS
7.3.7. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Drug Delivery Systems Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Injectable
8.3.3. Inhalation
8.3.4. Ocular
8.3.5. Nasal
8.3.6. Topical
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Drug Delivery Systems Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Drug Delivery Systems Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type of Delivery System, 2017–2031
10.3.1. Intrauterine Implants
10.3.2. Prodrug Implants
10.3.3. Polymeric Drug Delivery
10.3.4. Targeted Drug Delivery
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Infectious Diseases
10.4.2. Oncology
10.4.3. Ophthalmology
10.4.4. Urology
10.4.5. Diabetes
10.4.6. CNS
10.4.7. Others
10.5. Market Value Forecast, by Route of Administration, 2017–2031
10.5.1. Oral
10.5.2. Injectable
10.5.3. Inhalation
10.5.4. Ocular
10.5.5. Nasal
10.5.6. Topical
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Type of Delivery System
10.7.2. By Application
10.7.3. By Route of Administration
10.7.4. By Country
11. Europe Drug Delivery Systems Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type of Delivery System, 2017–2031
11.3.1. Intrauterine Implants
11.3.2. Prodrug Implants
11.3.3. Polymeric Drug Delivery
11.3.4. Targeted Drug Delivery
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Infectious Diseases
11.4.2. Oncology
11.4.3. Ophthalmology
11.4.4. Urology
11.4.5. Diabetes
11.4.6. CNS
11.4.7. Others
11.5. Market Value Forecast, by Route of Administration, 2017–2031
11.5.1. Oral
11.5.2. Injectable
11.5.3. Inhalation
11.5.4. Ocular
11.5.5. Nasal
11.5.6. Topical
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Type of Delivery System
11.7.2. By Application
11.7.3. By Route of Administration
11.7.4. By Country/Sub-region
12. Asia Pacific Drug Delivery Systems Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type of Delivery System, 2017–2031
12.3.1. Intrauterine Implants
12.3.2. Prodrug Implants
12.3.3. Polymeric Drug Delivery
12.3.4. Targeted Drug Delivery
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Infectious Diseases
12.4.2. Oncology
12.4.3. Ophthalmology
12.4.4. Urology
12.4.5. Diabetes
12.4.6. CNS
12.4.7. Others
12.5. Market Value Forecast, by Route of Administration, 2017–2031
12.5.1. Oral
12.5.2. Injectable
12.5.3. Inhalation
12.5.4. Ocular
12.5.5. Nasal
12.5.6. Topical
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Type of Delivery System
12.7.2. By Application
12.7.3. By Route of Administration
12.7.4. By Country/Sub-region
13. Latin America Drug Delivery Systems Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type of Delivery System, 2017–2031
13.3.1. Intrauterine Implants
13.3.2. Prodrug Implants
13.3.3. Polymeric Drug Delivery
13.3.4. Targeted Drug Delivery
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Infectious Diseases
13.4.2. Oncology
13.4.3. Ophthalmology
13.4.4. Urology
13.4.5. Diabetes
13.4.6. CNS
13.4.7. Others
13.5. Market Value Forecast, by Route of Administration, 2017–2031
13.5.1. Oral
13.5.2. Injectable
13.5.3. Inhalation
13.5.4. Ocular
13.5.5. Nasal
13.5.6. Topical
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Type of Delivery System
13.7.2. By Application
13.7.3. By Route of Administration
13.7.4. By Country/Sub-region
14. Middle East & Africa Drug Delivery Systems Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Type of Delivery System, 2017–2031
14.3.1. Intrauterine Implants
14.3.2. Prodrug Implants
14.3.3. Polymeric Drug Delivery
14.3.4. Targeted Drug Delivery
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Infectious Diseases
14.4.2. Oncology
14.4.3. Ophthalmology
14.4.4. Urology
14.4.5. Diabetes
14.4.6. CNS
14.4.7. Others
14.5. Market Value Forecast, by Route of Administration, 2017–2031
14.5.1. Oral
14.5.2. Injectable
14.5.3. Inhalation
14.5.4. Ocular
14.5.5. Nasal
14.5.6. Topical
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Type of Delivery System
14.7.2. By Application
14.7.3. By Route of Administration
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Amgen Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. F. Hoffmann-La Roche Ltd.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Pfizer Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Johnson & Johnson Services, Ltd.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Becton, Dickinson and Company
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. AstraZeneca plc
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Baxter International, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Bayer AG
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Boston Scientific Corporation
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Drug Delivery Systems Market Size (US$ Mn) Forecast, by Type of Delivery System, 2017–2031
Table 02: Global Drug Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Drug Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Drug Delivery Systems Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Drug Delivery Systems Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Drug Delivery Systems Market Size (US$ Mn) Forecast, by Type of Delivery System, 2017–2031
Table 07: North America Drug Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 08: North America Drug Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 09: Europe Drug Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Drug Delivery Systems Market Size (US$ Mn) Forecast, by Type of Delivery System, 2017–2031
Table 11: Europe Drug Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 12: Europe Drug Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 13: Asia Pacific Drug Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Drug Delivery Systems Market Size (US$ Mn) Forecast, by Type of Delivery System, 2017–2031
Table 15: Asia Pacific Drug Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Asia Pacific Drug Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 17: Latin America Drug Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Drug Delivery Systems Market Size (US$ Mn) Forecast, by Type of Delivery System, 2017–2031
Table 19: Latin America Drug Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Latin America Drug Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 21: Middle East & Africa Drug Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Drug Delivery Systems Market Size (US$ Mn) Forecast, by Type of Delivery System, 2017–2031
Table 23: Middle East & Africa Drug Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Middle East & Africa Drug Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
List of Figures
Figure 01: Global Drug Delivery Systems Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Drug Delivery Systems Market Revenue (US$ Mn), by Type of Delivery System, 2022
Figure 03: Global Drug Delivery Systems Market Value Share, by Type of Delivery System, 2022
Figure 04: Global Drug Delivery Systems Market Revenue (US$ Mn), by Application, 2022
Figure 05: Global Drug Delivery Systems Market Value Share, by Application, 2022
Figure 06: Global Drug Delivery Systems Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 07: Global Drug Delivery Systems Market Value Share, by Route of Administration, 2022
Figure 08: Global Drug Delivery Systems Market Value Share, by Region, 2022
Figure 09: Global Drug Delivery Systems Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Drug Delivery Systems Market Value Share Analysis, by Type of Delivery System, 2022–2031
Figure 11: Global Drug Delivery Systems Market Attractiveness Analysis, by Type of Delivery System, 2023-2031
Figure 12: Global Drug Delivery Systems Market Value Share Analysis, by Application, 2022–2031
Figure 13: Global Drug Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
Figure 14: Global Drug Delivery Systems Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 15: Global Drug Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 16: Global Drug Delivery Systems Market Value Share Analysis, by Region, 2022–2031
Figure 17: Global Drug Delivery Systems Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Drug Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Drug Delivery Systems Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Drug Delivery Systems Market Value Share Analysis, by Country, 2022–2031
Figure 21: North America Drug Delivery Systems Market Value Share Analysis, by Type of Delivery System, 2022–2031
Figure 22: North America Drug Delivery Systems Market Value Share Analysis, by Application, 2022–2031
Figure 23: North America Drug Delivery Systems Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 24: North America Drug Delivery Systems Market Attractiveness Analysis, by Type of Delivery System, 2023–2031
Figure 25: North America Drug Delivery Systems Market Attractiveness Analysis, by Application, 2023–2031
Figure 26: North America Drug Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 27: Europe Drug Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Drug Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 30: Europe Drug Delivery Systems Market Value Share Analysis, by Type of Delivery System, 2022–2031
Figure 31: Europe Drug Delivery Systems Market Value Share Analysis, by Application, 2022–2031
Figure 32: Europe Drug Delivery Systems Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 33: Europe Drug Delivery Systems Market Attractiveness Analysis, by Type of Delivery System, 2023–2031
Figure 34: Europe Drug Delivery Systems Market Attractiveness Analysis, by Application, 2023–2031
Figure 35: Europe Drug Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 36: Asia Pacific Drug Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Drug Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 39: Asia Pacific Drug Delivery Systems Market Value Share Analysis, by Type of Delivery System, 2022–2031
Figure 40: Asia Pacific Drug Delivery Systems Market Value Share Analysis, by Application, 2022–2031
Figure 41: Asia Pacific Drug Delivery Systems Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 42: Asia Pacific Drug Delivery Systems Market Attractiveness Analysis, by Type of Delivery System, 2023–2031
Figure 43: Asia Pacific Drug Delivery Systems Market Attractiveness Analysis, by Application, 2023–2031
Figure 44: Asia Pacific Drug Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 45: Latin America Drug Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Drug Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 48: Latin America Drug Delivery Systems Market Value Share Analysis, by Type of Delivery System, 2022–2031
Figure 49: Latin America Drug Delivery Systems Market Value Share Analysis, by Application, 2022–2031
Figure 50: Latin America Drug Delivery Systems Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 51: Latin America Drug Delivery Systems Market Attractiveness Analysis, by Type of Delivery System, 2023–2031
Figure 52: Latin America Drug Delivery Systems Market Attractiveness Analysis, by Application, 2023–2031
Figure 53: Latin America Drug Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 54: Middle East & Africa Drug Delivery Systems Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Drug Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Drug Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 57: Middle East & Africa Drug Delivery Systems Market Value Share Analysis, by Type of Delivery System, 2022–2031
Figure 58: Middle East & Africa Drug Delivery Systems Market Value Share Analysis, by Application, 2022–2031
Figure 59: Middle East & Africa Drug Delivery Systems Market Value Share Analysis, by Route of Administration, 2022–2031
Figure 60: Middle East & Africa Drug Delivery Systems Market Attractiveness Analysis, by Type of Delivery System, 2023–2031
Figure 61: Middle East & Africa Drug Delivery Systems Market Attractiveness Analysis, by Application, 2023–2031
Figure 62: Middle East & Africa Drug Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023–203
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Drug Delivery Systems Market
